Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT05654571

Weight Loss and Breast Cancer

Evaluation of the Relationship Between Weight Loss and Breast Cancer After Laparoscopic Sleeve Gastrectomy Surgery

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
Fatih Sultan Mehmet Training and Research Hospital · Academic / Other
Sex
Female
Age
40 Years
Healthy volunteers
Not accepted

Summary

Obesity is an important risk factor for postmenopausal breast cancer. A large meta-analysis concluded that obesity is associated with a 20% to 40% increased risk for receptor-positive postmenopausal breast cancer. The International Agency for Research on Cancer working group on obesity and cancer risk drew similar conclusions. Obesity seems to have the opposite effect among premenopausal women, with most studies suggesting that higher BMI is associated with a reduced risk of premenopausal breast cancer. Determining whether deliberate weight loss is associated with a reduced risk of breast cancer is difficult in part because sustained weight loss is difficult to achieve and few studies have sufficient statistical power to address this question. Bariatric surgery is one of the few weight loss interventions in which significant weight loss is maintained. A limited number of previous studies have suggested a reduced risk of cancer following bariatric surgery. Recently, it showed that bariatric surgery is associated with a lower risk of several types of cancer, including an approximately 40 % reduction in the risk of postmenopausal breast cancer. However, whether bariatric surgery affects breast cancer risk in premenopausal women and whether this association is altered by estrogen receptor (ER) status has not been addressed. The aim of this study is to examine the relationship between weight loss after laparoscopic sleeve gastrectomy (LSG) and breast cancer.

Detailed description

In this study, 300 female patients who underwent laparoscopic sleeve gastrectomy due to morbid obesity in Fatih Sultan Mehmet Training and Research Hospital General Surgery Clinic will be included. The number of samples was calculated by performing impact power analysis. Mamagrophy is recommended for all women over the age of 40 as part of the routine cancer screening program in our country. For this reason, it is assumed that female patients over the age of 40 who have undergone LSG operation have undergone mammography as of 2022. For this reason, the data of these patients will be examined by scanning from the hospital system. Patients who have undergone mammography examination at least 3 years after the LSG operation will be included in the study. The mammograms of the patients who underwent mammography in January 2015 and later will be evaluated. The final diagnosis of breast cancer will be made with the pathology result in patients with suspicious appearance on mamagrophy. If there is a malignancy detected as a result of the examinations, its size and pathology will be recorded. Patients' age, gender, and total weight loss will be recorded. In this retrospective study, we aimed to determine the incidence of breast cancer in patients who had undergone LSG surgery and also to determine whether there was a change in breast cancer compared to weight loss. The patient inclusion criteria are as follows: * 40 years and older (age as of 2022, not the age of operation) * LSG was applied in our clinic due to morbid obesity. * Patients whose mamagrofi images are available in the hospital system The patient exclusion criteria are as follows: * Patients who underwent abdominal surgery again after LSG * Patients whose mamagrophy image is not in the system * Patients with suspicious findings as a result of mammography and who did not undergo additional imaging or biopsy * Patients out of follow-up after the operation

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTmammographyAll patients are checked for mammography every year after surgery.

Timeline

Start date
2022-12-15
Primary completion
2026-01-01
Completion
2026-05-01
First posted
2022-12-16
Last updated
2022-12-16

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT05654571. Inclusion in this directory is not an endorsement.